The recommendations, published June 18 in JAMA, replace the task force’s 2017 guidance that recommended providers screen children for obesity. The task force considers the guidance a B recommendation, indicating a high degree of certainty of moderate benefits and requiring most private health insurance plans to cover treatment without a copay.
The updated recommendations do not include prescribing GLP-1 drugs.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
